title: Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome.
abstract: We aimed to evaluate the efficacy of tadalafil 5 mg once-daily treatment on testosterone levels in patients with erectile dysfunction (ED) accompanied by the metabolic syndrome. A total of 40 men with metabolic syndrome were evaluated for ED in this study. All the patients received 5 mg tadalafil once a day for 3 months. Erectile function was assessed using the five-item version of the International Index of Erectile Function (IIEF) questionnaire. Serum testosterone, follicle-stimulating hormone and luteinising hormone levels were also evaluated, and blood samples were taken between 08.00 and 10.00 in the fasting state. All participants have three or more criteria of metabolic syndrome. At the end of 3 months, mean testosterone values and IIEF scores showed an improvement from baseline values (from 3.6 ± 0.5 to 5.2 ± 0.3, from 11.3 ± 1.9 to 19 ± 0.8 respectively). After the treatment, serum LH levels were decreased (from 5.6 ± 0.6 to 4.6 ± 0.5). There was significantly difference in terms of baseline testosterone and luteinising hormone values and IIEF scores (p < .05). Based on our findings, we recommend tadalafil 5 mg once daily in those men with erectile dysfunction especially low testosterone levels accompanied by metabolic syndrome.
authors.affiliation: Department of Urology, Derince Training and Research Hospital, Kocaeli, Turkey.
authors.forename: L
authors.initials: L
authors.lastname: Ozcan
authors.affiliation: Department of Urology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
authors.forename: E C
authors.initials: EC
authors.lastname: Polat
authors.affiliation: Department of Urology, Medical Faculty, Kafkas University, Kars, Turkey.
authors.forename: R
authors.initials: R
authors.lastname: Kocaaslan
authors.affiliation: Department of Urology, Derince Training and Research Hospital, Kocaeli, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Onen
authors.affiliation: Department of Urology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Otunctemur
authors.affiliation: Department of Urology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Ozbek
mesh_terms: D000328:Adult; D000368:Aged; D007172:Erectile Dysfunction / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications*; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D000068581:Tadalafil / Q000494:pharmacology / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D013739:Testosterone; D000068581:Tadalafil
keywords: erectile dysfunction; tadalafil; testosterone